3The executive board has today discussed and approved the annual report of G2B BioSolutions Denmark ApS for the financial year 1 January - 31 December 2024.The annual report is prepared in accordance with the Danish Financial Statements Act.In my opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2024 and of the results of the company's operations for the financial year 1 January - 31 December 2024.In my opinion, management's review includes a fair review of the matters dealt with in the management's review.Management recommends that the annual report should be approved by the company in general meeting.Dayanand Suryabhan JadhavDirectorTo the shareholder of G2B BioSolutions Denmark ApSWe have compiled the financial statements of G2B BioSolutions Denmark ApS for the financial year 1 January - 31 December 2024 based on the company's bookkeeping records and other information made available by enterprise. The financial statements comprises a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes. We performed the engagement in accordance with ISRS 4410, Compilation Engagements. We have applied our professional expertise to assist the enterprise in the preparation and presentation of the financial statements in accordance with the Danish Financial Statements Act. We complied with the relevant provisions of the Danish Act on Approved Auditors and with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), including principles relating to integrity, objectivity, professional competence and due care. The financial statements and the accuracy and completeness of the information used to compile the financial statements are the enterprise´s responsibility. As a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information provided by enterprise for our compilation of the financial statements. Accordingly, we do not express an audit or a review conclusion on whether the financial statements have been prepared in accordance with the Danish Financial Statements Act.Hellerup2025-05-27Søren JonassenStatsautoriseret revisormne18488Jamal Oliver Naveed JanjooaStatsautoriseret revisormne49080Business review The company's purpose is to engage in business activities involving trade, services, production, and other activities related thereto as deemed appropriate by management.Financial review The company's income statement for the year ended 31 December 2024 shows a loss of DKK 9.563, and the balance sheet at 31 December 2024 shows equity of DKK 20.340. A letter of support has been issued by the owners.Significant events occurring after the end of the financial year No events have occurred after the balance sheet date which could significantly affect the company's financial position.The annual report of G2B BioSolutions Denmark ApS for 2024 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to reporting class B entities, as well as provisions applying to reporting class C entities. The accounting policies applied are consistent with those of last year. The annual report for 2024 is presented in DKKIncome is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement. Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably. Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company and the value of the liability can be measured reliably. On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item. Certain financial assets and liabilities are measured at amortised cost using the effective interest method. Amortised cost is calculated as the historic cost less any installments and plus/less the accumulated amortisation of the difference between the cost and the nominal amount. On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date.In pursuance of section 32 of the Danish Financial Statements Act, the company does not disclose its revenue. Gross profit includes other external costs.Other external costs includes administration costs.Financial income and expenses are recognized in the income statement at the amounts relating to the financial year. Financial items include interest income and interest expenses.Tax for the year, which comprises the current tax charge for the year and changes in the deferred tax charge, is recognised in the income statement as regards the portion that relates to the profit/loss for the year and directly in equity as regards the portion that relates to entries directly in equity.Cash and cash equivalents include deposits with financial institutions.Dividends Proposed dividends are disclosed as a separate item under equity. Dividends are recognised as a liability when declared by the annual general meeting of shareholders.Liabilities, which include trade payables, payables to group entities and other payables, are measured at amortised cost, which is usually equivalent to nominal value.-9313-50002505097-9563-1009700-9563-10097-9563-100972034034903203403490320340349034000040000-19660-100972034029903050000500005000203403490340000-10097-956340000-19660A letter of support has been issued by the owners.0009725050002505097The company is jointly taxed with its parent company, Dayanand Jadhav Holding ApS (the administration company), and is jointly and severally liable with the other jointly taxed companies for the payment of corporate income tax for the income year 2022 and onwards, as well as for withholding tax on dividends, interest, and royalties falling due for payment on or after 1 July 2025 The company is secondarily liable for the joint taxation income of the other affiliated companies in the group, and such liability is limited solely to the ownership share by which the company is included in the group.None.Årsrapport33256876CroweRygårds Allé 1042900 Hellerup2024-01-012024-12-312023-01-012023-12-3143237748G2B BioSolutions Denmark ApSHagens Alle72900HellerupDKDanmark2022-05-04GentofteCrowe33256876Søren JonassenStatsautoriseret revisorRygårds Allé1042900HellerupDKDanmark39292500info@crowe.dk2025-05-27Dayanand Suryabhan JadhavRegnskabsklasse BtrueAndre erklæringer uden sikkerhedCaseWare-FSR432377482024-01-012024-12-31432377482024-01-012024-12-311432377482024-01-012024-12-312432377482023-01-012023-12-31432377482023-12-31432377482024-12-31432377482024-01-012024-12-311432377482024-01-01h:ContributedCapitalMember432377482024-12-31h:ContributedCapitalMember432377482024-01-01h:RetainedEarningsMember432377482024-01-012024-12-31h:RetainedEarningsMember432377482024-12-31h:RetainedEarningsMemberiso4217:DKKxbrli:pure